Short-term responders of non-small cell lung cancer patients to EGFR tyrosine kinase inhibitors display high prevalence of TP53 mutations and primary resistance mechanisms

被引：0
|
作者：
Fan, Y. [1 ]
Xu, Y. [1 ]
Tong, X. [2 ]
Yan, J. [3 ]
Wu, X. [2 ]
Shao, Y. W. [2 ]
机构：
[1] Zhejiang Canc Hosp, Key Lab Diag & Treatment Technol Thorac Canc, Hangzhou, Zhejiang, Peoples R China
[2] Geneseeq Technol Inc, Translat Med Res Inst, Toronto, ON, Canada
[3] Nanjing Geneseeq Technol Inc, Med Dept, Nanjing, Jiangsu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
157P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Short-Term Responders of Non-Small Cell Lung Cancer Patients to EGFR Tyrosine Kinase Inhibitors Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms
    Xu, Yanjun
    Tong, Xiaoling
    Yan, Junrong
    Wu, Xue
    Shao, Yang W.
    Fan, Yun
    TRANSLATIONAL ONCOLOGY, 2018, 11 (06): : 1364 - 1369
  • [2] The prevalence of TP53 mutation and primary resistance mechanisms in short-term responders to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Fan, Yun
    Tong, Xiaoling
    Yan, Junrong
    Wu, Xue
    Shao, Yang
    Xu, Yanjun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Short-Term Responders of NSCLC to EGFR-TKIs Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms
    Xu, Y.
    Tong, X.
    Yan, J.
    Wu, X.
    Shao, Y. W.
    Fan, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S803 - S804
  • [4] TP53 Mutations as Mechanisms of Primary and Acquired Resistance to Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated NSCLC
    Canale, M.
    Ludovini, V.
    Crino, L.
    Dazzi, C.
    Chiadini, E.
    Capelli, L.
    Papi, M.
    Mariotti, M.
    De Luigi, N.
    Minuti, G.
    Calistri, D.
    Baglivo, S.
    Chiari, R.
    Bonafe, M.
    Delmonte, A.
    Ulivi, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S591 - S591
  • [5] Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
    Krawczyk, Pawel
    Mlak, Radoslaw
    Powrozek, Tomasz
    Nicos, Marcin
    Kowalski, Dariusz M.
    Wojas-Krawczyk, Kamila
    Milanowski, Janusz
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2012, 16 (05): : 401 - 406
  • [6] TP53 Mutations Could Involve in EGFR-TKI Primary Resistance in Advanced Non-Small Cell Lung Cancer
    Li, X.
    Su, C.
    Ren, S.
    Zhao, C.
    Jiang, T.
    Chen, X.
    Li, J.
    Li, W.
    Gao, G.
    Zhou, F.
    Shao, Y.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2227 - S2227
  • [7] TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer
    Lee, Eung Bae
    Jin, Guang
    Lee, Shin Yup
    Park, Ji Young
    Kim, Min Jung
    Choi, Jin Eun
    Jeon, Hyo Sung
    Cha, Seung Ick
    Cho, Sukki
    Kim, Chang Ho
    Park, Tae-In
    Jung, Tae Hoon
    Son, Ji-Woong
    Park, Jae Yong
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2010, 25 (05) : 698 - 705
  • [8] Identification of novel mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
    de Bruin, Elza C.
    Cowell, Catherine F.
    Howell, Michael
    Varmus, Harold E.
    Politi, Katerina
    Downward, Julian
    CANCER RESEARCH, 2011, 71
  • [9] Elucidating mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC)
    Pao, William
    Miller, Vincent A.
    Kris, Mark G.
    Varmus, Harold E.
    ANNALS OF ONCOLOGY, 2004, 15 : 4 - 4
  • [10] Drug Resistance to EGFR Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer
    Shien, Kazuhiko
    Yamamoto, Hiromasa
    Soh, Junichi
    Miyoshi, Shinichiro
    Toyooka, Shinichi
    ACTA MEDICA OKAYAMA, 2014, 68 (04) : 191 - 200
12345